Long-Term Zinc Supplementation Improves Liver Function and Decreases the Risk of Developing Hepatocellular Carcinoma
| Autor: | Atsushi Hosui, Kengo Matsumoto, Takashi Tanimoto, Motohiro Hirao, Naoki Hiramatsu, Yuka Sueyoshi, Takuya Yamada, Eiji Kimura, Yukihiro Kusumoto, Kousaku Onishi, Sumiko Abe |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Carcinoma Hepatocellular Liver fibrosis gastroenterology chemistry.chemical_element lcsh:TX341-641 Zinc Zn concentration Gastroenterology Article 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Cumulative incidence In patient HCC Aged Retrospective Studies Aged 80 and over Nutrition and Dietetics business.industry Incidence Liver Neoplasms zinc Middle Aged medicine.disease Liver chemistry liver function 030220 oncology & carcinogenesis Hepatocellular carcinoma Dietary Supplements Female 030211 gastroenterology & hepatology Liver function business lcsh:Nutrition. Foods and food supply Food Science |
| Zdroj: | Nutrients, Vol 10, Iss 12, p 1955 (2018) Nutrients Volume 10 Issue 12 |
| ISSN: | 2072-6643 |
| DOI: | 10.3390/nu10121955 |
| Popis: | Zinc plays a pivotal role in various zinc enzymes, which are crucial in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. Whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development remains unknown. Two hundred and sixty-seven patients with CLDs who received a zinc preparation (Zn-group 196 patients), or who did not receive zinc (no Zn-treatment group 71 patients), were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were observed to be lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p < 0.001). According to serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations &ge 70 µ g/dL (p < 0.001). Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µ g/dL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|